Shenzhen JYMed Technology Co., Ltd. (JYMed) founded in 2009, is an innovative pharmaceutical enterprise with independent intellectual property rights in R&D, manufacturing and commercialization of peptide products. There are two subsidiary companies of Shenzhen JX Bio Pharmaceutical Co., Ltd. and Hubei JX Bio Pharmaceutical Co., Ltd. It is initiative to establish the R&D technology platform for peptide products and sustained release pharmaceutical preparation of peptide and protein medicines by JYMed in China. The peptide products in R&D are in the forward position in China and aboard, while the technology is in the domestic leading position and international advanced level. The company has an excellent R&D team, management team and first-class expert consultant team consisting of doctors, masters, professors, researchers, senior engineers and other professionals. Meanwhile, to maximally extend the R&D team by hiring top industry scientists to serve as visiting researchers, commissioners, and technical consultants and strengthening technical cooperation with scientific research units. It has established a good cooperative relationship with the University of Pittsburgh, the United States, Michigan State University, the University of Maryland, Peking University, Tsinghua University and other well-known domestic and foreign institutions and scientific research institutions. The company has passed the certification of Shenzhen High-tech Enterprise and National High-tech Enterprise. As a domestic enterprise with the advantage of the industrialization of polypeptide APIs, it has achieved a major technological breakthrough in the industrialization of polypeptide APIs with extremely high technical difficulty. With high-quality product quality, the company carries out open R&D CRO services. The market network covers domestic and foreign markets. The cooperation customers are mainly domestic and foreign large-scale new drug R&D and production companies.